Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 58 - 60 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.01643 İndeks Tarihi: 18-07-2022
Brodalumab
Öz: Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75
response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic
psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.
Anahtar Kelime: Brodalumab
Öz: Brodalumab interlökin-17 (IL-17) reseptörüne bağlanarak IL-17 yolağını inhibe eden insan kaynaklı bir monoklonal antikordur. Klinik
araştırmalarda, 12. haftada hastaların %82 ila 84’ünde PAŞİ75 yanıtı elde edilmiştir. Generalize püstüler ve eritrodermik psoriasiste de etkili
olduğu gösterilmiştir. Diğer IL-17 inhibitörlerinde olduğu gibi inflamatuar barsak hastalığı olanlarda dikkatli kullanılmalıdır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tomalin LE, Russell CB, Garcet S, et al.: Short-term transcriptional response to IL-17 receptor-a antagonism in the treatment of psoriasis. J Allergy Clin Immunol 2019;S0091-6749:32599.
- 2. Guttman-Yassky E, Krueger JG: IL-17C: A unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol 2018;138:1467-9.
- 3. Salinger DH, Endres CJ, Martin DA, Gibbs MA: A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. Clin Pharmacol Drug Dev 2014;3:276-83.
- 4. Endres CJ, Salinger DH, Köck K, et al.: Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol 2014;54:1230-8.
- 5. European Medicines Agency. Summary of product characteristics: Kyntheum 210 mg solution for injection in pre-filled syringe. 2017. http://www.ema. europa.eu
- 6. Papp KA, Reich K, Paul C, et al.: A prospective phase III, randomized, doubleblind, placebo-controlled study of brodalumab in patients with moderate- tosevereplaquepsoriasis. Br J Dermatol 2016;175:273-86.
- 7. Lebwohl M, Strober B, Menter A, et al.: Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015;373:1318- 28.
- 8. Facheris P, Valenti M, Pavia G, et al.: Brodalumab: A new way to inhibit IL-17 in psoriasis. Dermatol Ther 2020;33:e13403.
- 9. Yamasaki K, Nakagawa H, Kubo Y, Ootaki K: Japanese Brodalumab study group: Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, openlabel study. Br J Dermatol 2017;176:741-51.
- 10. Nakagawa H, Niiro H, Ootaki K, Japanese brodalumab study group: Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 2016;81:44-52.
| APA | borlu m (2022). Brodalumab . , 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| Chicago | borlu murat Brodalumab . (2022): 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| MLA | borlu murat Brodalumab . , 2022, ss.58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| AMA | borlu m Brodalumab . . 2022; 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| Vancouver | borlu m Brodalumab . . 2022; 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| IEEE | borlu m "Brodalumab ." , ss.58 - 60, 2022. 10.4274/turkderm.galenos.2022.01643 |
| ISNAD | borlu, murat. "Brodalumab ". (2022), 58-60. https://doi.org/10.4274/turkderm.galenos.2022.01643 |
| APA | borlu m (2022). Brodalumab . Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| Chicago | borlu murat Brodalumab . Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| MLA | borlu murat Brodalumab . Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| AMA | borlu m Brodalumab . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| Vancouver | borlu m Brodalumab . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 58 - 60. 10.4274/turkderm.galenos.2022.01643 |
| IEEE | borlu m "Brodalumab ." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.58 - 60, 2022. 10.4274/turkderm.galenos.2022.01643 |
| ISNAD | borlu, murat. "Brodalumab ". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 58-60. https://doi.org/10.4274/turkderm.galenos.2022.01643 |
